Shares of Tiziana Life Sciences (NASDAQ:TLSA) jumped 12% Thursday after the company said that a study of its drug candidate intranasal foralumab in the treatment of traumatic brain injury has been published in Nature Neuroscience.
Tiziana(NASDAQ:TLSA) said the study demonstrated that nasal administration of foralumab, an anti-CD3 monoclonal antibody, significantly reduced neuroinflammation and improved recovery.
The study also showed that modulating the neuroinflammatory response correlated with improved neurological outcomes, such as less anxiety, less cognitive decline and improved motor skills, in a preclinical model of traumatic brain injury, according to a statement.
Tiziana (TLSA) added that the findings could translate into the treatment of intercerebral hemorrhage or stroke.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.